This early phase I trial evaluates how well 18F-FAZA positron emission tomography/magnetic resonance imaging (PET/MRI) scans work in checking oxygen level of the tumor area in patients with high grade glioma or cervical cancer. Hypoxia (a low level of oxygen in the blood) may cause both 1) certain treatments to not be effective, and 2) tumors to be more aggressive. 18F-FAZA is a type of drug called a radiotracer that, along with the PET/MRI scan, is used to help see what areas of the body have lower oxygen levels.
Additional locations may be listed on ClinicalTrials.gov for NCT05047913.
Locations matching your search criteria
United States
Texas
Houston
M D Anderson Cancer CenterStatus: Temporarily closed to accrual
Contact: Caroline Chung
Phone: 713-745-5422
PRIMARY OBJECTIVE:
I. To investigate the relationship between dynamic magnetic resonance imaging (MRI) (tumor perfusion [dynamic susceptibility contrast (DSC)] and permeability [dynamic contrast-enhanced (DCE)]) and dynamic fluorine F 18-fluoroazomycin arabinoside (18F-FAZA) positron emission tomography (PET) uptake.
SECONDARY OBJECTIVES:
I. To investigate the relationship between tumor hypoxia (defined by quantitative blood oxygen level-dependent [qBOLD] and 18F-FAZA PET) and pathological features including proportionate necrosis, Ki-67 and IDH mutation status.
II. To investigate the correlation between the hypoxic tumor region delineated using 18F-FAZA PET and qBOLD.
OUTLINE: Patients are assigned to 1 of 2 cohorts.
GLIOMA COHORT: Patients with gliomas receive 18F-FAZA intravenously (IV) and undergo PET/MRI scan over 50 minutes.
CERVICAL COHORT: Patients with cervical cancer receive 18F-FAZA IV and undergo PET/MRI or PET/computed tomography (CT) over 2 hours.
After completion of study, patients are followed up at 24 hours and again at 30 days.
Lead OrganizationM D Anderson Cancer Center
Principal InvestigatorCaroline Chung
